Treating bone metastases with local therapy in a breast cancer patient resulted in decreased pain and prevented fracture.

Abstract

Lytic lesions from bone metastases from breast, lung and prostate carcinomas, are associated with a poor prognosis and significant morbidities that include fracture and debilitating pain. Chemotherapeutics, palliative radiation therapy and surgical intervention are routinely used to treat these lesions. The ZetaMet™ Bone Graft is a novel antitumorigenic and osteoinductive graft that offers a potential alternative treatment option. ZetaMet is composed of calcium phosphate salts, type-I collagen and the small molecule N-allyl noroxymorphone dihydrate. Here, we report the case of a stage IV breast cancer patient with multiple lytic metastatic lesions to the spine that were successfully treated, which led to a significant reduction in pain and increased quality of life. This outcome demonstrates that a locally administered therapeutic intervention may represent an important alternative for patients with bone metastases that warrants further study.

• Authors: David Palma, Nikhil Thakur, Joe C Loy, Bryan S Margulies
• Journal: Pain management (Pain Manag) Vol. 13 Issue 10 Pg. 569-577 (Oct 2023) ISSN: 1758-1877 [Electronic] England
• PMID: 37795710 (Publication Type: Case Reports, Journal Article)

Topics

• Humans
• Bone Neoplasms (complications, therapy)
• Breast Neoplasms (complications, therapy)
• Fractures, Bone
• Pain
• Quality of Life
• Female